Here, we reported the rare case of primary pleural squamous cell carcinoma (PPSCC) in a 71-year-old male patient. After chemo and targeted therapies, the patient showed continuous tumor progression and clinical deterioration. Fortunately, the patient had a high expression level of PD-L1 (80%) in the tumor tissues. Ultimately, the patient survived for additional 6 months with camrelizumab treatment. In summary, camrelizumab may be a good candidate for the treatment of PPSCC, especially in tumors with high PD-L1 expression.

中文翻译：

---

原发性胸膜鳞状细胞癌，高阳性 PD-L1，对 Camrelizumab 显示显着反应：病例报告

在这里，我们报告了一名 71 岁男性患者的罕见原发性胸膜鳞状细胞癌 (PPSCC)。在化疗和靶向治疗后，患者表现出持续的肿瘤进展和临床恶化。幸运的是，患者的肿瘤组织中PD-L1的表达水平很高（80%）。最终，患者在接受卡瑞珠单抗治疗后又存活了 6 个月。综上所述，camrelizumab 可能是治疗 PPSCC 的良好候选药物，尤其是在 PD-L1 高表达的肿瘤中。